Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome

Magar Ghazarian; Xavier S. Revelo; Mark K. Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A. Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D’Angelo; Peter Horton; William C. Chapman; Diane Brockmeier; Minna Woo; Edgar G. Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J. Gehring; Shawn Winer; Daniel A. Winer

doi:10.1126/sciimmunol.aai7616

Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome

Magar Ghazarian, Xavier S. Revelo, Mark K. Nøhr, Helen Luck, Kejing Zeng, Helena Lei, Sue Tsai, Stephanie A. Schroer, Yoo Jin Park, Melissa Hui Yen Chng, Lei Shen, June Ann D’Angelo, Peter Horton, William C. Chapman, Diane Brockmeier, Minna Woo, Edgar G. Engleman, Oyedele Adeyi, Naoto Hirano, Tianru JinAdam J. Gehring, Shawn Winer, Daniel A. Winer

Research output: Contribution to journal › Article › peer-review

138 Scopus citations

Abstract

Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8⁺ T cell subsets, which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8⁺ T cells represent a dominant intrahepatic immune cell population that is linked to glucose dysregulation. Accumulation and activation of these cells are supported by type I interferon (IFN-I) responses in the liver. Livers from obese mice up-regulate critical interferon regulatory factors (IRFs), interferon stimulatory genes (ISGs), and IFN protein, whereas IFNR1^−/− mice or CD8-specific IFNR1^−/− chimeric mice are protected from disease. IFNR1 inhibitors improve metabolic parameters in mice, whereas CD8⁺ T cells and IFN-I responses correlate with NAFLD in human patients. Thus, IFN-I responses represent a central immunological axis that governs intrahepatic T cell pathogenicity during metabolic disease.

Original language	English (US)
Article number	eaai7616
Journal	Science Immunology
Volume	2
Issue number	10
DOIs	https://doi.org/10.1126/sciimmunol.aai7616
State	Published - 2017

Bibliographical note

Funding Information:
We thank P. Ohashi for discussing the results. All other authors discussed the results and/or reviewed the manuscript. This work was supported, in part, by the Canadian Institutes of Health Research (CIHR) grants 119414, 132562, 142708, and 148385 (to D.A.W.); Canadian Diabetes Association (CDA) grants OG-3-15-5014 and CS-5-12-3886 (to D.A.W.); and J.P. Bickell Foundation Grant (to D.A.W.). D.A.W. received a Canada Research Chair and the Ontario Ministry of Innovation Early Researcher Award. M.G. received a CIHR Canada Graduate Scholarship–Master’s Program award. M.K.N. is the recipient of an Alfred Benzon Foundation Postdoctoral Fellowship, and X.S.R. is the recipient of a CDA Postdoctoral Fellowship Award.

Publisher Copyright:
2017 © The Authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1126/sciimmunol.aai7616

http://europepmc.org/articles/pmc5447456

Find It

Find It at U of M Libraries

Cite this

Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., Shen, L., D’Angelo, J. A., Horton, P., Chapman, W. C., Brockmeier, D., Woo, M., Engleman, E. G., Adeyi, O., Hirano, N., ... Winer, D. A. (2017). Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Science Immunology, 2(10), Article eaai7616. https://doi.org/10.1126/sciimmunol.aai7616

Ghazarian, M, Revelo, XS, Nøhr, MK, Luck, H, Zeng, K, Lei, H, Tsai, S, Schroer, SA, Park, YJ, Chng, MHY, Shen, L, D’Angelo, JA, Horton, P, Chapman, WC, Brockmeier, D, Woo, M, Engleman, EG, Adeyi, O, Hirano, N, Jin, T, Gehring, AJ, Winer, S & Winer, DA 2017, 'Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome', Science Immunology, vol. 2, no. 10, eaai7616. https://doi.org/10.1126/sciimmunol.aai7616

@article{f5af27e4fa934a3ab39f3caa1230ce1f,

title = "Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome",

abstract = "Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8+ T cell subsets, which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8+ T cells represent a dominant intrahepatic immune cell population that is linked to glucose dysregulation. Accumulation and activation of these cells are supported by type I interferon (IFN-I) responses in the liver. Livers from obese mice up-regulate critical interferon regulatory factors (IRFs), interferon stimulatory genes (ISGs), and IFN protein, whereas IFNR1−/− mice or CD8-specific IFNR1−/− chimeric mice are protected from disease. IFNR1 inhibitors improve metabolic parameters in mice, whereas CD8+ T cells and IFN-I responses correlate with NAFLD in human patients. Thus, IFN-I responses represent a central immunological axis that governs intrahepatic T cell pathogenicity during metabolic disease.",

author = "Magar Ghazarian and Revelo, {Xavier S.} and N{\o}hr, {Mark K.} and Helen Luck and Kejing Zeng and Helena Lei and Sue Tsai and Schroer, {Stephanie A.} and Park, {Yoo Jin} and Chng, {Melissa Hui Yen} and Lei Shen and D{\textquoteright}Angelo, {June Ann} and Peter Horton and Chapman, {William C.} and Diane Brockmeier and Minna Woo and Engleman, {Edgar G.} and Oyedele Adeyi and Naoto Hirano and Tianru Jin and Gehring, {Adam J.} and Shawn Winer and Winer, {Daniel A.}",

note = "Funding Information: We thank P. Ohashi for discussing the results. All other authors discussed the results and/or reviewed the manuscript. This work was supported, in part, by the Canadian Institutes of Health Research (CIHR) grants 119414, 132562, 142708, and 148385 (to D.A.W.); Canadian Diabetes Association (CDA) grants OG-3-15-5014 and CS-5-12-3886 (to D.A.W.); and J.P. Bickell Foundation Grant (to D.A.W.). D.A.W. received a Canada Research Chair and the Ontario Ministry of Innovation Early Researcher Award. M.G. received a CIHR Canada Graduate Scholarship–Master{\textquoteright}s Program award. M.K.N. is the recipient of an Alfred Benzon Foundation Postdoctoral Fellowship, and X.S.R. is the recipient of a CDA Postdoctoral Fellowship Award. Publisher Copyright: 2017 {\textcopyright} The Authors.",

year = "2017",

doi = "10.1126/sciimmunol.aai7616",

language = "English (US)",

volume = "2",

journal = "Science Immunology",

issn = "2470-9468",

publisher = "American Association for the Advancement of Science",

number = "10",

}

TY - JOUR

T1 - Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome

AU - Ghazarian, Magar

AU - Revelo, Xavier S.

AU - Nøhr, Mark K.

AU - Luck, Helen

AU - Zeng, Kejing

AU - Lei, Helena

AU - Tsai, Sue

AU - Schroer, Stephanie A.

AU - Park, Yoo Jin

AU - Chng, Melissa Hui Yen

AU - Shen, Lei

AU - D’Angelo, June Ann

AU - Horton, Peter

AU - Chapman, William C.

AU - Brockmeier, Diane

AU - Woo, Minna

AU - Engleman, Edgar G.

AU - Adeyi, Oyedele

AU - Hirano, Naoto

AU - Jin, Tianru

AU - Gehring, Adam J.

AU - Winer, Shawn

AU - Winer, Daniel A.

N1 - Funding Information: We thank P. Ohashi for discussing the results. All other authors discussed the results and/or reviewed the manuscript. This work was supported, in part, by the Canadian Institutes of Health Research (CIHR) grants 119414, 132562, 142708, and 148385 (to D.A.W.); Canadian Diabetes Association (CDA) grants OG-3-15-5014 and CS-5-12-3886 (to D.A.W.); and J.P. Bickell Foundation Grant (to D.A.W.). D.A.W. received a Canada Research Chair and the Ontario Ministry of Innovation Early Researcher Award. M.G. received a CIHR Canada Graduate Scholarship–Master’s Program award. M.K.N. is the recipient of an Alfred Benzon Foundation Postdoctoral Fellowship, and X.S.R. is the recipient of a CDA Postdoctoral Fellowship Award. Publisher Copyright: 2017 © The Authors.

PY - 2017

Y1 - 2017

N2 - Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8+ T cell subsets, which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8+ T cells represent a dominant intrahepatic immune cell population that is linked to glucose dysregulation. Accumulation and activation of these cells are supported by type I interferon (IFN-I) responses in the liver. Livers from obese mice up-regulate critical interferon regulatory factors (IRFs), interferon stimulatory genes (ISGs), and IFN protein, whereas IFNR1−/− mice or CD8-specific IFNR1−/− chimeric mice are protected from disease. IFNR1 inhibitors improve metabolic parameters in mice, whereas CD8+ T cells and IFN-I responses correlate with NAFLD in human patients. Thus, IFN-I responses represent a central immunological axis that governs intrahepatic T cell pathogenicity during metabolic disease.

AB - Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8+ T cell subsets, which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8+ T cells represent a dominant intrahepatic immune cell population that is linked to glucose dysregulation. Accumulation and activation of these cells are supported by type I interferon (IFN-I) responses in the liver. Livers from obese mice up-regulate critical interferon regulatory factors (IRFs), interferon stimulatory genes (ISGs), and IFN protein, whereas IFNR1−/− mice or CD8-specific IFNR1−/− chimeric mice are protected from disease. IFNR1 inhibitors improve metabolic parameters in mice, whereas CD8+ T cells and IFN-I responses correlate with NAFLD in human patients. Thus, IFN-I responses represent a central immunological axis that governs intrahepatic T cell pathogenicity during metabolic disease.

UR - http://www.scopus.com/inward/record.url?scp=85029575247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029575247&partnerID=8YFLogxK

U2 - 10.1126/sciimmunol.aai7616

DO - 10.1126/sciimmunol.aai7616

M3 - Article

AN - SCOPUS:85029575247

SN - 2470-9468

VL - 2

JO - Science Immunology

JF - Science Immunology

IS - 10

M1 - eaai7616

ER -

Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this